THERAPEUTIC STUDIES OF ANAPLASTIC GLIOMAS

描述：(申请人描述) 这项提案是作为与 脑肿瘤治疗新方法(NABTT)的其他成员 财团(项目负责人：Henry Brem医学博士和斯图尔特·格罗斯曼医学博士； 约翰霍普金斯大学协调中心)，以便设计和 进行第一阶段和第二阶段的治疗方案 间变性胶质瘤。这项建议的主要目标是改善 这是对患有原发性脑肿瘤的成人患者的转归。我们建议 通过将我们的临床研究优势与 NABTT联盟(布朗大学， 哥伦比亚大学，埃默里大学，H.Lee Moffitt癌症中心，亨利 福特医院，约翰霍普金斯大学，马萨诸塞州综合医院， 西北大学、维克森林大学、华盛顿大学、 阿拉巴马大学伯明翰分校，宾夕法尼亚大学，以及 德克萨斯大学圣安东尼奥分校)。我们的特殊优势是 为NABTT联盟带来的机构包括：1)大量 患有原发脑肿瘤且转诊网络完善的患者，2) 一个致力于脑瘤的多学科临床团队，已经在 10年以上，3)丰富的临床和实验室资源，4) 大量由美国国立卫生研究院资助的脑瘤实验室研究 计划，包括最近授予的脑瘤计划项目赠款 (P01 NS34856，Steven Rosenfeld，医学博士，首席调查员)，AS 以及一些产业界和学术界的联系，以支持 校园神经肿瘤学研究，以及5)国家认可的 癌症研究，包括生物统计和数据管理，在 癌症治疗的临床药理学，在功能神经成像， 并在进行机构和合作的第一和第二阶段 临床试验。因此，这项建议建立在我们广泛的临床基础上 在既定背景下的调查专业知识 多机构脑肿瘤治疗联盟。

DESCRIPTION: (Applicant's Description) This proposal is being submitted as part of a cooperative agreement with other members of the New Approaches to Brain Tumor Therapy (NABTT) Consortium (Project Leaders: Henry Brem, M.D. and Stewart Grossman, M.D.; Coordinating Center, Johns Hopkins University), in order to design and conduct Phase I and Phase II treatment protocols for patients with anaplastic gliomas. The primary objective of this proposal is to improve the outcome for adult patients with primary brain tumors. We propose to address this goal by combining our clinical investigative strengths with those of the other members of the NABTT Consortium (Brown University, Columbia University, Emory University, H. Lee Moffitt Cancer Center, Henry Ford Hospital, Johns Hopkins University, Massachusetts General Hospital, Northwestern University, Wake Forest University, Washington University, University of Alabama at Birmingham, University of Pennsylvania, and University of Texas at San Antonio). The particular strengths that our institution brings to the NABTT Consortium include: 1) a large number of patients with primary brain tumors and a well-developed referral network, 2) a brain tumor-dedicated multidisciplinary clinical team that has been in place for over ten years, 3) extensive clinical and laboratory resources, 4) a significant number of NIH-supported brain tumor laboratory research programs, including a recently-awarded Brain Tumor Program P r oject Grant (P01 NS34856, Steven Rosenfeld, M.D., Ph.D., Principal Investigator), as well as a number of industrial-academia contacts for support of neuro-oncology research on campus, and 5) nationally-recognized expertise in cancer research, including biostatistics and data management, in the clinical pharmacology of cancer therapeutics, in functional neuroimaging, and in the conducting of institutional and cooperative Phase I and II clinical trials. This proposal thus builds on our extensive clinical investigative expertise within the context of a well established multi-institutional brain tumor treatment consortium.